Conference Call with Akums Drugs & Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q1FY26 results Total income: Rs 1,051 crore compared to Rs 1,026 crore during Q1FY25, EBITDA: Rs 156 crore compared to Rs 111 crore during Q1FY25, EBITDA Margin: 14.8% for Q1FY26. PAT: Rs 65 crore compared to Rs 44 crore during Q1FY25, PAT Margin: 6.2% for Q1FY26. Sanjeev Jain, Managing Director, said: " This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor. " Sandeep Jain, Managing Director, said: "We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D;, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead. " Result PDF
Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Akums reported revenue of Rs 1,073 crore, reflecting a robust 12.4% year-on-year (YoY) growth. The company posted a 10.4% EBITDA margin with Adj EBITDA of 111 crore Adj PAT stood at Rs 44 crore for Q4FY25 compared to Rs 46 crore for Q4FY24 FY25 Financial Highlights: Akums closed FY25 with consolidated total income of Rs 4,170 crore An adjusted EBITDA margin of 12.3%, a 7-basis point improvement from the previous year with Adj EBITDA of 513 crore.. Adj PAT stood at Rs 234 crore for FY25 compared to Rs 220 crore for FY24 Commenting on the results, Sanjeev Jain, Managing Director, said: " As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums’ global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies." Sandeep Jain, Managing Director, added: "It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals—operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D; engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organization." Result PDF
Conference Call with Akums Drugs & Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.